News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
1–11
Matches
11
Sources here
7
Companies here
1
Search results Stored financial headlines

Active search

11 matching headlines

Ticker or company: VRAXMain company stories
Clear
Latest

The Globe and Mail Earnings

Virax Biolabs Boosts Liquidity, Secures Fosun Deal and Restores Nasdaq Compliance After Fiscal 2026 Report

Virax Biolabs Group Ltd. announced a significant improvement in its financial and operational standing after its fiscal 2026 report. The company boosted its liquidity with $6.4 million in cash and an additional $3.3 million from investment option exercises, secured a multi-country commercial supply agreement with Fosun Diagnostics, and regained Nasdaq compliance. These advancements, coupled with cost discipline and …

Main company 🇺🇸 United States
Read at The Globe and Mail
Sharemaestro market context Price below Trend Line 52 weeks -85.0% · Next-week setup negative 39.5% VRAX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Just inNext headlines
Sahm Earnings Main company 🇺🇸 United States

12 Health Care Stocks Moving In Thursday's Pre-Market Session

This article lists 12 healthcare stocks that experienced significant movement in Thursday's pre-market session. It details the top gainers, including AtaiBeckley, Agape ATP, Liminatus Pharma, GH Research, Virax Biolabs Group, and Kairos Pharma, along with their percentage increases and market values. The article also …

VRAX main company
Sharemaestro market context Price below Trend Line 52 weeks -85.0% · Next-week setup negative 39.5% VRAX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Sahm Earnings Main company 🇺🇸 United States

Virax Biolabs' CEO James Foster Provides Shareholder Update Following Fiscal 2026 Annual Report and Fosun Diagnostics Commercial Supply Agreement

Virax Biolabs' CEO James Foster issued a shareholder update discussing the company's fiscal 2026 annual report and recent developments. Key highlights include $6.4 million in cash, a commercial supply agreement with Fosun Diagnostics for ImmuneSelect in six Southeast Asian markets, and regaining Nasdaq compliance. …

VRAX main company
Sharemaestro market context Price below Trend Line 52 weeks -85.0% · Next-week setup negative 39.5% VRAX stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context